CC
PRDS

Centiva Capital’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Centiva Capital’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,000
Closed -$189K – 1717
2021
Q1 		$189K Buy
+19,000
New +$196K 0.01% 1008

Other funds holding PRDS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
JCM
JS Capital Management New York $223M AUM 104.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $41.5M AUM 245.82% 1-Year Est. Return

Centiva Capital's PRDS Position: Q2 2021 in Review

Centiva Capital sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2021, closing a stake of 19,000 shares — an estimated $189K sold.

Centiva Capital first reported a position in PRDS in Q1 2021 and held it in 1 quarter. The position peaked at $189K in Q1 2021. 69 funds tracked by Wall St. Rank hold PRDS as of Q2 2021.

  • Centiva Capital reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Centiva Capital sold 19,000 Pardes Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $189K.
  • Centiva Capital first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Centiva Capital's Pardes Biosciences, Inc. Common Stock position peaked at $189K in Q1 2021.
  • 69 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2021.

Based on Centiva Capital's 13F filing for Q2 2021, filed 16 Aug 2021.